Kadcyla (trastuzumab emtansine)


Kadcyla is an antibody-drug conjugate (ADC) engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1.

Kadcyla is approved as a single agent in over 100 countries, including the US and EU, for the treatment of people with HER2-positive advanced breast cancer who have previously received Herceptin and taxane-based chemotherapy, either separately or in combination. Kadcyla is also approved in the US and EU for the adjuvant (post-surgery) treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant (pre-surgery) treatment that included Herceptin and taxane-based chemotherapy.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.